Roche, Chugai’s Enspryng falls short of expectations in myasthenia gravis study

21 Mar 2024
firstwordpharma.com
Phase 3Clinical ResultDrug Approval
Despite achieving the primary endpoint of a Phase III study in generalised myasthenia gravis (gMG), Chugai Pharmaceutical said that the benefit shown by Enspryng (satralizumab) “did not reach our expectations.” The news buoyed rival argenx, which markets Vyvgart (efgartigimod alfa) for gMG, with the company’s shares climbing 15% on Thursday.
The LUMINESCE trial randomised 188 adults and adolescents 12 years of age and older with gMG to receive Enspryng or placebo, both in combination with standard-of-care therapy. Chugai noted that statistically significant data was seen for the primary endpoint of mean change from baseline in total Myasthenia Gravis Activities of Daily Living (MG-ADL) score at 24 weeks in the anti-AChR-seropositive population.
Approval of Vvygart, including in the US and Europe, was based on findings from the Phase III ADAPT trial in which 68% of anti-AChR-antibody-positive gMG patients were responders on the MG-ADL scale following treatment with the drug, versus 30% for placebo.
Roche leery ahead of data
Ahead of the readout, analysts at Jefferies had highlighted comments made by Chugai’s partner Roche earlier this year as suggesting that theLUMINESCE data may not be as compelling as hoped. The analysts also noted that Roche did not include Enspryng as one of its key growth drivers for 2025 and beyond.
While Chugai provided no further details from LUMINESCE, it indicated that Enspryng was well tolerated in the study. Detailed results will be presented at the upcoming American Academy of Neurology (AAN) annual meeting.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.